Creating new non-addictive pain relief options for neuropathic pain
Official title: Development of non-opioid, non-addictive analgesics for treating neuropathic pain
Funded at Northeastern University · NIH-11058796 · Data updated 2026-11-12
This study is working on creating new pain relief medications that help with nerve pain without using opioids, so they won't be addictive and can provide safe relief for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northeastern University NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 18, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $675,107 |
| NIH project number | 1R01NS137079-01A1 |
| Project ID | NIH-11058796 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals experiencing neuropathic pain who are seeking alternative pain relief methods.
✕Less likely to help
Patients who do not suffer from neuropathic pain or have other underlying conditions that contraindicate participation may not benefit from this research.
What this research studies
This research focuses on developing new types of pain relief medications that do not rely on opioids and are not addictive. It aims to create dual-action compounds that can effectively manage neuropathic pain by targeting specific receptors in the body without causing the side effects commonly associated with traditional pain medications. The research involves synthesizing novel compounds and testing their effectiveness in preclinical models to ensure they provide safe and effective pain relief. Patients may benefit from these new treatments that aim to alleviate pain without the risk of addiction.
Why it matters
Potential benefit: If successful, this research could lead to safer pain management options for patients suffering from neuropathic pain.
How similar studies have gone: Previous research has shown promise in developing non-addictive pain relief methods, but this approach using dualsteric modulators is relatively novel.
Where this research is happening
-
Northeastern University
Boston, United States Active
Researchers
- Principal investigator: Thakur, Ganesh a — Northeastern University
- Study coordinator: Thakur, Ganesh a
Related research
Other NIH-funded projects on the same topics.
-
Peripheral nerve stimulation for chronic neuropathic pain in a new mechanistic trial
A study at Stanford tests whether a painless-sounding electrical nerve treatment helps people with long-standing neuropathic pain when added to standard care.
-
Keratinocytes and nerve pain in chemotherapy patients
A study tests a new approach to reduce painful nerve damage from chemotherapy by targeting skin cells called keratinocytes.
-
High-frequency brain stimulation for trigeminal neuropathic pain
A large, multi-site trial tests a non-invasive brain stimulation method to relieve chronic facial nerve pain for adults who have not found relief from other treatments.
-
Programmable lithium-delivery devices for pain relief without motor loss
A new bioelectronic system uses a safe lithium source and AI-powered control to deliver targeted pain relief for neuropathic pain, aiming to spare motor function.
-
Glial-nerve conversations in neuropathic pain and diabetes
This grant looks at how supportive brain and nerve cells communicate with pain-sensing neurons to understand and reduce chronic nerve pain in people.
-
Parmodulins with Low Abuse Potential for Neuropathic Pain
A new class of pain medicines called parmodulins is being studied to help people with nerve-pain pain without high abuse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.